

## Evaluation Report for Category B, Subcategories 2.1, 2.3, 2.4, 2.5 Application

**Application Number:** 2021-6157  
**Application:** New End-use product (Product Chemistry) – Guarantee, Identity of Formulants, Proportion of Formulants, and Formulation Type  
**Product:** Flint Extra Fungicide  
**Registration Number:** 34962  
**Active ingredient (a.i.):** Trifloxystrobin  
**PMRA Document Number:** 3503576

### Purpose of Application

The purpose of this application was to register a commercial end-use product, Flint Extra Fungicide, for the control or suppression of certain diseases in grapes, pome fruits, asparagus, sugarbeet, stone fruits, celery, Chinese celery, root vegetables, strawberry, peanut and hazelnuts.

### Chemistry Assessment

Flint Extra Fungicide is formulated as a suspension containing trifloxystrobin at a concentration of 485 g/L. This end-use product has a density of 1.14 g/mL and pH of 7.7 (10% dilution). The required chemistry data for Flint Extra Fungicide has been provided, reviewed and found to be acceptable.

### Health Assessments

Flint Extra Fungicide was considered toxicologically equivalent to the precedent product; therefore, no toxicology data were required. Flint Extra Fungicide is considered to be of low acute toxicity via oral, inhalation, and dermal routes. Flint Extra Fungicide is considered to be non-irritating to the eyes and minimally irritating to the skin and is not considered to be a dermal sensitizer.

The uses of Flint Extra Fungicide to control various fungal pests on labelled crops do not fit within the registered use pattern of trifloxystrobin since the end-use product is a new formulation type. The product is formulated as a suspension concentrate, which required an updated mixer/loader/applicator quantitative risk assessment. No health risks of concern were identified for mixers, loaders and applicators, provided that workers wear the recommended personal protective equipment and use the recommended engineering controls. For postapplication workers, an updated quantitative postapplication worker exposure assessment was also conducted. No health risks of concern were identified for postapplication workers provided that workers respect the recommended restricted-entry intervals. For residential postapplication exposure, no health risks of concern were identified. No health risks of concern for bystanders are expected when label directions, precautions and instructions are followed.

No new residue data for trifloxystrobin in various crops were submitted or were required to support the registration of Flint Extra Fungicide. Previously reviewed residue data from field trials conducted in/on various crops were reassessed in the framework of this application. In addition, processing studies in treated crops were also reassessed to determine the potential for concentration of residues of trifloxystrobin into processed commodities.

Based on this assessment, residues of trifloxystrobin are not expected to be greater than that for the currently registered uses and will be covered by the established maximum residue limits (MRLs). Consequently, dietary exposure to trifloxystrobin is not expected to increase with the registration of Flint Extra Fungicide and will not pose health risks of concern to any segment of the population, including infants, children, adults, and seniors.

### **Environmental Assessment**

The registered use pattern of Flint Extra Fungicide is similar to the registered use pattern of the precedent product, therefore, no additional risk is expected from the use of Flint Extra Fungicide.

The label includes all the required environmental precautions, directions for use and spray buffer zones information which adequately mitigate risks to the environment.

Risk from use of Flint Extra Fungicide is acceptable from the environmental perspective when used according to label directions.

### **Value Assessment**

Rationales and results from efficacy trials conducted in the USA, Mexico, New Zealand and South Africa between 2004 and 2011 were submitted in support of the use claims on the Flint Extra Fungicide label. Overall, Flint Extra Fungicide was demonstrated to be comparable in terms of efficacy when applied as a foliar application to the registered wettable granular formulation at similar rates in efficacy trials. Flint Extra Fungicide, at the labeled rates, controlled diseases tested in efficacy trials. The supporting evidence confirmed the value of Flint Extra Fungicide against diseases on labelled crops.

The registration of Flint Extra Fungicide will provide Canadian growers with a new product to manage these important diseases on label-listed crops.

### **Conclusion**

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information acceptable to support the registration of Flint Extra Fungicide.

## References

### PMRA

#### Document

Number	Reference
3292111	2004, Product chemistry of GEM SC fungicide, DACO: 3,3.2,3.4.1
3292112	2003, Physical and chemical properties of Gem 500 SC (USF 2004 500 SC), DACO: 3.1,3.5,3.5.1,3.5.10,3.5.11,3.5.12,3.5.14,3.5.2,3.5.3,3.5.4,3.5.5, 3.5.6,3.5.7,3.5.8,3.5.9 CBI
3393776	2001, Brookfield Viscosity Method, DACO: 3.5 CBI
3393777	2002, Specific Gravity Determination of Aqueous Flowable Formulations, DACO: 3.5 CBI
3393778	2000, Determination of pH of Water, Flowables and Solids, DACO: 3.5 CBI
3393779	1998, Appearance, DACO: 3.5 CBI
3393785	2022, Bridging storage stability data from Trifloxystrobin SC 500 g/L to Trifloxystrobin SC 485 (485 g/L), DACO: 3.5.10 CBI
3393786	2002, A10610A Storage Stability and Shelf Life Statement (2 years 20C) in packaging made of HDPE, DACO: 3.5.10 CBI
3393787	2000, Bulk Odor, DACO: 3.5 CBI
3292124	2021, Value Assessment of CGA279202 485 SC Fungicide on Various Diseases in Multiple Crops, DACO: 10.1
3405534	2021, Compilation of Trial Reports, DACO: 10.2.3

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2023

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.